Absci (id:8290 ABSI)
2.56 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:31:53 PM)
Exchange closed, opens in 14 hours 58 minutes
About Absci
Market Capitalization 312.41M
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.
| Headquarters (address) |
18105 SE Mill Plain Boulevard Vancouver 98683 WA United States |
| Phone | 360 949 1041 |
| Website | https://www.absci.com |
| Employees | 155 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ABSI |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.35 - 6.72 |
| Market Capitalization | 312.41M |
| P/E trailing | -2.13 |
| P/E forward | -3.77 |
| Price/Sale | 74.26 |
| Price/Book | 1.52 |
| Beta | 2.19 |
| EPS | -0.920 |
| EPS United States (ID:6, base:3402) | 24.22 |